AUTHORS
David Bond, MD, BS, Ahmed Ghobashi2, Rosario Distefano3, John Reneau, MD, PhD4, Beth Christian, MD5, Jonathan Brammer, MD6, Robert A Baiocchi, MD, PhD7, Timothy J Voorhees, MD,MSc8, Audrey Sigmund, MD9, John T Patton, MD, PhD10, Yazeed Sawalha, MD11, Kami Maddocks, MD12, Anjun Ma13, Stephen Maxted Ansell, MD, PhD14, Qin Ma, PhD15, Lapo Alinari, MD, PhD16, Patrizia Mondello, MD, PhD17
AFFILIATIONS
1 Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
2 Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
3 Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
4 Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
5 Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
6 Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
7 Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
8 Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
9 Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
10 Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
11 Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
12 Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
13 Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
16 Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
17 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Introduction: Programmed cell death protein 1 (PD-1) inhibitor therapy is a cornerstone of treatment for patients (pts) with Hodgkin lymphoma (HL); however, PD-1 inhibitor monotherapy rarely induces durable remission, highlighting the need for combination strategies to overcome resistance. We previously reported results from a phase 1/2 study of nivolumab plus lenalidomide (Nivo/Len) in relapsed/refractory (R/R) HL (Bond et al, ICML 2023), including 13 pts with an overall response rate of 70% and complete response (CR) rate of 38%. Outcomes were particularly favorable among pts achieving CR, all of whom remain progression-free. To investigate mechanisms associated with treatment response, we performed single-cell RNA-sequencing (scRNA-seq) of peripheral blood from pts treated with Nivo/Len and longitudinally compared immune profiles between pts achieving CR and those who did not.
Methods: Peripheral blood samples were collected from pts with R/R HL before treatment and after two cycles (C2) of Nivo/Len as part of a phase 1b study (NCT03015896) conducted between April 28, 2017 to April 9, 2024. Response assessment by PET/CT was performed after C2. Paired samples were available for 12 pts, including 4 pts with CR, 5 with partial response (PR), and 3 with progressive disease (PD). scRNA-seq was performed using the 10X Genomics Flex v1 platform. An independent scRNA-seq dataset from DFCI (Paczkowska et al, Nat Commun 2024) was used for validation.
Results:
UMAP clustering distinguished B cells from immune cells, with immune cells further resolved into 13 transcriptionally distinct subsets, including T cells (3 clusters), NK (3 clusters), monocytes (6 clusters), and plasmacytoid dendritic cells. Higher resolution T-cell analysis identified memory-like (Tcm, CD4+ Tm), effector-like (Teff), cytotoxic-like (CTL), regulatory (Tregs), and oxidative phosphorylation (Oxphos) populations, each comprising active or exhausted (exh) states. Compared to pts with non-CR (PR+SD), pts achieving CR demonstrated enrichment of activated CD8+ T cells both at baseline (log2FC 4.06, FDR 0.0015) and after C2 (log2FC 1.32, FDR 0.0011). In contrast, non-CR pts exhibited persistent enrichment of both CD8+ CTL T cells and exh CTL cells across both timepoints (FDR 0.0011), consistent with sustained antigen stimulation and dysfunctional antitumor immunity. Differential expression analysis demonstrated increased expression of inflammatory genes (e.g., IFNG, TNF, IRF1) and canonical NF-kB signaling (e.g., NFKBIA, NFKBIZ, RELB) in T-cell subsets from non-CR pts. Despite this inflammatory transcriptional profile, immune response signaling pathways declined after C2 in non-CR pts, suggesting progressive immune dysfunction. These findings were validated in the independent DFCI cohort, in which pts in CR showed enrichment of activated CXCR5+ T cells, whereas non-responders were enriched for CD8+ CTL T cells. Consistent with prior observations in PD-1 monotherapy, L1β+ monocytes were enriched in non-CR pts treated with Nivo/Len (log2FC 2.12 FDR 0.0074). Gene set enrichment analysis demonstrated upregulation of inflammatory immune response and canonical NF-kB signaling pathways. CellChat analysis identified reduced pro-inflammatory TNF and TGF signaling with concordant upregulation of the immunosuppressive Visfatin signaling axis. NK cells were nearly absent in pts achieving CR but progressively expanded in pts with PR and SD, with NK-T cells representing the predominant subset. Unlike other immune populations, NK-T cells demonstrated enrichment of interferon- response signatures accompanied by suppression of mTOC1 and NF-kB signaling. Functional validation studies are ongoing.
Conclusions: Response to nivolumab plus lenalidomide in R/R HL is associated with distinct peripheral immune states. Durable CR is characterized by enrichment of activated and antigen-experienced CD8+ T-cell populations, whereas failure to achieve CR is associated with persistent exhausted cytotoxic T cells, inflammatory NF-κB signaling, expansion of IL1β+ monocytes, and increased NK-T cells. These findings identify candidate mechanisms of resistance to PD-1–based therapy and suggest immune pathways that may be therapeutically targeted to improve response durability.
DISCLOSURES
David Bond, MD, BS: OncLive - Honoraria; Accutar - Research Funding; Genmab - Research Funding; Kite Pharma - Research Funding; Nurix Therapeutics - Research Funding; Bristol Myers Squibb - Research Funding; Incyte Corporation - Research Funding; BeOne Medicines, Ltd - Research Funding; ADC Therapeutics - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony)